Lamdong Pharmaceutical JSC (HNX:LDP)
7,700.00
+100.00 (1.32%)
At close: Nov 3, 2026
HNX:LDP Revenue
Lamdong Pharmaceutical JSC had revenue of 75.28B VND in the quarter ending September 30, 2026, with 27.22% growth. This brings the company's total for the last twelve months to 278.17B, up 15.00% year-over-year. In the year 2025, Lamdong Pharmaceutical JSC had annual revenue of 243.91B with 11.91% growth. That makes Lamdong Pharmaceutical JSC the 37,016th largest company in the world by revenue and 534th in Vietnam.
Revenue (ttm)
278.17B
Revenue Growth
+15.00%
P/S Ratio
0.51
Revenue / Employee
1.07B
Employees
261
Market Cap
144.21B
Revenue by Segment
- Manufacture 160.14B 65.7%
- Trading 80.97B 33.2%
- Others 2.80B 1.1%
Fiscal year ended Dec 31, 2025 See the full HNX:LDP breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 243.91B | 25.95B | 11.91% |
| Dec 31, 2024 | 217.96B | 31.96B | 17.18% |
| Dec 31, 2023 | 186.00B | -1.41B | -0.75% |
| Dec 31, 2022 | 187.41B | 25.51B | 15.76% |
| Dec 31, 2021 | 161.90B | -217.76B | -57.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vidipha Central Pharmaceutical JSC | 1.01T |
| Ben Tre Pharmaceutical JSC | 873.41B |
| Pharmedic Pharmaceutical Medicinal JSC | 565.40B |
| Central Pharmaceutical Joint Stock Company No3 | 524.41B |
| Mediplantex National Pharmaceutical JSC | 434.97B |
| Vimedimex Medi-Pharma JSC | 310.29B |
| SPM Corporation | 202.60B |
| Phong Phu Pharmaceutical JSC | 167.82B |